Liraglutide vs Mazdutide

Liraglutide is a GLP-1 receptor agonist already FDA-approved and sold under the brand names Saxenda and Victoza for treating type 2 diabetes, obesity, and reducing cardiovascular risk. Mazdutide, on the other hand, is a dual GLP-1 and glucagon receptor agonist still in development (not yet FDA-approved) and has no branded products or approved uses at this time.

AI summary of the sources below.